-
Mashup Score: 0Use of ARATs as First-line mHSPC Treatment Grows | GU Oncology Now - 10 month(s) ago
Researchers studied various trials including LATITUDE, STAMPEDE, ENZAMET, and ARCHES to determine similar characteristics among various ARAT treatments.
Source: GU Oncology NowCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
New research has reported updates on the primary OS analysis of the ENZAMET trial to define the benefit of enzalutamide treatment in various prognostic subgroups.
Source: GU Oncology NowCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Please wait whilst we redirect you - 1 year(s) ago
About ScienceDirectRemote accessShopping cartAdvertiseContact and supportTerms and conditionsPrivacy policyWe use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.Copyright © 2023 Elsevier B.V. or its licensors or contributors. ScienceDirect® is a registered trademark of Elsevier B.V.ScienceDirect® is a registered trademark…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 14Please wait whilst we redirect you - 1 year(s) ago
About ScienceDirectRemote accessShopping cartAdvertiseContact and supportTerms and conditionsPrivacy policyWe use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.Copyright © 2023 Elsevier B.V. or its licensors or contributors. ScienceDirect® is a registered trademark of Elsevier B.V.ScienceDirect® is a registered trademark…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2How Does the Data from the PEACE-1, ARASENS and ENZAMET Studies Inform Clinical Practice? - Karim Fizazi - 1 year(s) ago
Karim Fizazi and Alicia Morgans discuss the latest ENZAMET updates shared at ASCO 2022. Dr. Fizazi considers the data from the ENZAMET study within the context of findings from the PEACE-1 AND ARASENS trials. In considering the data from these studies, Dr. Fizazi concludes by sharing his treatment recommendations for patients with de novo high volume MET versus de novo low volume MET, as well…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Overall Survival Outcomes in ENZAMET (ANZUP 1304), Trial of Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer - Ian Davis - 1 year(s) ago
Ian Davis joins Alicia Morgans in discussing the overall survival (OS) outcomes in ENZAMET (ANZUP 1304), an international, cooperative group randomized phase three cooperative group, open label study, looking at the addition of enzalutamide, for patients with metastatic hormone-sensitive prostate cancer, commencing therapy. At this year’s ASCO meeting, Ian Davis presented the updated OS…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0How Does the Data from the PEACE-1, ARASENS and ENZAMET Studies Inform Clinical Practice? - Karim Fizazi - 1 year(s) ago
Karim Fizazi and Alicia Morgans discuss the latest ENZAMET updates shared at ASCO 2022. Dr. Fizazi considers the data from the ENZAMET study within the context of findings from the PEACE-1 AND ARASENS trials. In considering the data from these studies, Dr. Fizazi concludes by sharing his treatment recommendations for patients with de novo high volume MET versus de novo low volume MET, as well…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Overall Survival Outcomes in ENZAMET (ANZUP 1304), Trial of Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer - Ian Davis - 1 year(s) ago
Ian Davis joins Alicia Morgans in discussing the overall survival (OS) outcomes in ENZAMET (ANZUP 1304), an international, cooperative group randomized phase three cooperative group, open label study, looking at the addition of enzalutamide, for patients with metastatic hormone-sensitive prostate cancer, commencing therapy. At this year’s ASCO meeting, Ian Davis presented the updated OS…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0How Does the Data from the PEACE-1, ARASENS and ENZAMET Studies Inform Clinical Practice? - Karim Fizazi - 1 year(s) ago
Karim Fizazi and Alicia Morgans discuss the latest ENZAMET updates shared at ASCO 2022. Dr. Fizazi considers the data from the ENZAMET study within the context of findings from the PEACE-1 AND ARASENS trials. In considering the data from these studies, Dr. Fizazi concludes by sharing his treatment recommendations for patients with de novo high volume MET versus de novo low volume MET, as well…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Overall Survival Outcomes in ENZAMET (ANZUP 1304), Trial of Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer - Ian Davis - 2 year(s) ago
Ian Davis joins Alicia Morgans in discussing the overall survival (OS) outcomes in ENZAMET (ANZUP 1304), an international, cooperative group randomized phase three cooperative group, open label study, looking at the addition of enzalutamide, for patients with metastatic hormone-sensitive prostate cancer, commencing therapy. At this year’s ASCO meeting, Ian Davis presented the updated OS…
Source: UroTodayCategories: Latest Headlines, UrologyTweet
Researchers from Japan examined untreated patients with #mHSPC who were part of various trials, including LATITUDE and #ENZAMET, to determine similar characteristics among various ARAT treatments, and how changes in the usage of ARATs occurred over time: https://t.co/oGHbjq1fWB https://t.co/Rh4p1G2H4d